Legend Biotech (LEGN) Prepaid Assets (2019 - 2026)
Legend Biotech's (LEGN) quarterly Prepaid Assets came in at $209.3 million in Q1 2026, up 14.97% YoY from $182.0 million in Q1 2025, and down 17.4% on a QoQ basis from $253.4 million in Q4 2025.
Legend Biotech (LEGN) Prepaid Assets (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Prepaid Assets data on file, last reported at $209.3 million in Q1 2026.
- Quarterly Prepaid Assets rose 14.97% year-over-year to $209.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $209.3 million (up 14.97% YoY) and the FY2025 annual result came in at $253.4 million, up 93.44% from the prior year.
- Prepaid Assets declined to $209.3 million in Q1 2026, from $253.4 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $253.4 million in Q4 2025 to a low of $19.1 million in Q1 2022.
- A 5-year average of $123.2 million and a median of $100.6 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets jumped 183132.61% — and 2023, when it grew 12.14%.
- Tracing LEGN's Prepaid Assets over 5 years: stood at $61.8 million in 2022, then grew by 12.14% to $69.3 million in 2023, then surged by 89.17% to $131.0 million in 2024, then jumped by 93.44% to $253.4 million in 2025, then retreated by 17.4% to $209.3 million in 2026.
- The last three Prepaid Assets figures came in at $209.3 million (Q1 2026), $253.4 million (Q4 2025), and $219.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 221.30 Mn |
| Mar 31, 2026 | 209.30 Mn |
| Dec 31, 2025 | 253.40 Mn |
| Sep 30, 2025 | 218.99 Mn |
| Jun 30, 2025 | 219.08 Mn |
| Mar 31, 2025 | 182.04 Mn |
| Dec 31, 2024 | 131.00 Mn |
| Sep 30, 2024 | 112.80 Mn |
| Jun 30, 2024 | 100.63 Mn |
| Mar 31, 2024 | 85.60 Mn |
| Dec 31, 2023 | 69.25 Mn |
| Sep 30, 2023 | 66.57 Mn |
| Jun 30, 2023 | 66.57 Mn |
| Mar 31, 2023 | 51.76 Mn |
| Dec 31, 2022 | 61.76 Mn |
| Mar 31, 2022 | 19.10 Mn |
| Dec 31, 2021 | 13.85 Mn |
| Sep 30, 2021 | 13.84 Mn |
| Jun 30, 2021 | 11,170.00 |
| Mar 31, 2021 | 10,425.00 |